After spending five years in Australia to complete his training in research, John Stagg became co-holder of the Sabourin Family Pharmaceutical Chair in Women’s Health and began his teaching career at the Faculty of Pharmacy of the Université de Montréal. He specializes in the field of oncology and his research lab is integrated into the CHUM Research Centre.
Why Choosing Breast Cancer?
Because breast cancer is the most common cancer in women. In spite of major breakthroughs and the development of new drugs, some forms of breast cancer remain difficult to treat.
A Scientific Accomplishment You Are Proud of
My research has identified a new mechanism regulated by the CD73 enzyme, whereby cancer cells escape immunosurveillance (that is, the destruction by white blood cells). This discovery led to the development of new drugs that are currently the subject of clinical studies. My work also showed that treatment with Herceptin (breast cancer) can be improved when combined with an immunotherapy targeting the PD-1 molecule. This new treatment is also the subject of a clinical study.
- Cancer immunotherapy
- Development of new treatments
Sabourin Family Research Chair in Women’s Health
Projects Funded by the Foundation
2011 – Increase of immune response following the anti-ErbB-2 antibody treatment